Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corp director Vincent Bernadette N reported receiving 3,000 shares of common stock on February 6, 2026 under transaction code A, indicating an acquisition. The filing notes this represents a restricted stock unit (RSU) award that will vest in full on February 6, 2027. The shares were acquired at a stated price of $0 per share, leaving the director with 4,200 shares of beneficially owned common stock held directly after the grant.
SeaStar Medical Holding Corp director equity grant: Director Jennifer A. Baird received an award of 3,000 shares of common stock on February 6, 2026, reported at a price of $0 per share. After this grant, she beneficially owns 6,620 shares of the company’s common stock in direct ownership.
The 3,000-share award is structured as restricted stock units (RSUs) that will vest in full on February 6, 2027, meaning the shares are subject to a one-year service-based vesting period before becoming fully owned and freely transferable, subject to any company trading policies.
SeaStar Medical Holding Corp executive Towne Bradford K reported receiving 7,500 shares of common stock as a stock-based award. The shares, reported at a price of $0 per share, increased the executive's directly held stake to 9,050 shares.
The award is in the form of restricted stock units that vest in three equal installments on the first, second and third anniversaries of February 6, 2026. Towne Bradford K serves as the company's Principal Accounting Officer.
SeaStar Medical Holding Corp’s Chief Medical Officer Kevin Chung reported receiving 15,000 shares of common stock as a restricted stock unit (RSU) award on February 6, 2026. The RSUs vest in equal installments on the first, second, and third anniversaries of that date. After this grant, Chung beneficially owned 20,819 shares directly.
SeaStar Medical Holding Corp disclosed that its Chief Executive Officer, Eric Schlorff, received an award of 30,000 shares of common stock in the form of restricted stock units on February 6, 2026, at a grant price of $0 per share.
The RSU award vests in three equal installments on the first, second and third anniversaries of February 6, 2026. Following this grant, Schlorff beneficially owned 39,852 shares of SeaStar Medical common stock, held directly.
SeaStar Medical Holding Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement. On January 20, 2026, the company received confirmation from the Nasdaq Office of General Counsel that it once again meets the $1.00 minimum bid price standard set by Nasdaq Listing Rule 5550(a)(2). This means SeaStar Medical’s common stock and warrants continue to qualify for listing on The Nasdaq Stock Market, removing the immediate risk that its shares could be delisted solely for not meeting the bid price rule.
SeaStar Medical Holding Corporation is implementing a 1-for-10 reverse stock split of its common stock, approved at a special shareholder meeting and effective as of 12:01 a.m. Eastern on January 2, 2026. Every 10 existing shares will be combined into one new share, with no fractional shares issued; any fractional positions will be rounded up to the next whole share. All outstanding stock options and warrants will be proportionally adjusted, and the stock will continue trading on the Nasdaq Capital Market under the symbol ICU on a split-adjusted basis starting January 2, 2026. Immediately after the split, there will be approximately 3.8 million shares of common stock outstanding. Shareholders also approved reducing authorized common shares by 25,000,000 to a total of 425,000,000.
SeaStar Medical Holding Corp reported an initial insider ownership filing for its Chief Financial Officer, Michael Messinger. The report shows he beneficially owns 3,000 shares of common stock, held directly, as of 11/14/2025. This documents the equity stake of a key executive and does not describe any specific stock transactions.
SeaStar Medical Holding Corporation is registering the offer and sale of up to $1,901,000 of its common stock under an at-the-market program with H.C. Wainwright & Co. acting as sales agent. The company previously established an ATM facility with an aggregate offering price of $2,279,989, of which $1,170,258 of common stock had been sold as of November 6, 2025. This supplement amends the prior prospectus to align the maximum amount that may be sold with the limits of General Instruction I.B.6 of Form S-3, which currently permits offerings up to an aggregate price of $1,901,390. SeaStar’s public float held by non-affiliates is stated as $44,394,521, based on 35,802,033 shares at $1.24 per share, and the company notes it has sold $12,896,813 of common stock under these I.B.6 limits over the prior 12-month period.
SeaStar Medical Holding Corporation reported that its Board of Directors appointed Michael Messinger, age 51, as Chief Financial Officer, effective November 14, 2025. He brings more than two decades of finance and accounting experience in drug discovery and development, including serving as CFO of ContraFect Corporation from October 2018 to November 2023 and holding senior roles at Lexicon Pharmaceuticals and Coelacanth Corporation.
The company has engaged Mr. Messinger under a consulting agreement dated October 31, 2025, under which he will receive a monthly fee of $15,000, and the company may terminate the agreement at any time with 30 days’ notice. SeaStar also filed the consulting agreement and a press release announcing his appointment as exhibits.